{"id":"NCT01371565","sponsor":"Corcept Therapeutics","briefTitle":"Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome","officialTitle":"Compassionate Use Protocol for the Administration of CORLUX® (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-11","primaryCompletion":"2012-06","completion":"2012-09","firstPosted":"2011-06-13","resultsPosted":"2013-11-20","lastUpdate":"2014-03-18"},"enrollment":4,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Cushing's Disease","Cushing's Syndrome"],"interventions":[{"type":"DRUG","name":"Mifepristone","otherNames":["CORLUX®"]}],"arms":[{"label":"mifepristone","type":"EXPERIMENTAL"}],"summary":"This is a compassionate use study. In addition to providing compassionate use access to mifepristone, objectives of the study will be to evaluate the safety and utility of mifepristone in the treatment of the signs and symptoms of endogenous Cushing's syndrome when given on a compassionate use basis. The study will only enroll subjects whose physicians have determined that medical treatment is needed to control the symptoms or signs of hypercortisolemia.","primaryOutcome":{"measure":"Number of Participants With Adverse Events","timeFrame":"6 months","effectByArm":[{"arm":"Mifepristone","deltaMin":4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":9},"locations":{"siteCount":5,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":4},"commonTop":["Blood potassium decreased","Hypoglycaemia","Pancytopenia","Eye irritation","Dysphagia"]}}